OBJECTIVE: To evaluate the effect of oral treosulfan in patients with platinum-resistant ovarian cancer. METHODS: A phase II trial of oral treosulfan 500 mg per day in 30 females with platinum resistant ovarian cancer. All patients had measurable or evaluable disease. RESULTS: The treatment was well tolerated. One patient (3%) achieved a partial response lasting 12+ months. Seven patients had stable disease for 5.3 months (median) range 4.4-7.5 months. Median time to progression was 11.5 weeks (95% C.L. 11-12 weeks). Median survival was 31 weeks (95% C.L. 30-35 weeks). CONCLUSION: Oral treosulfan in the present schedule is not recommended in platinum resistant ovarian cancer.
OBJECTIVE: To evaluate the effect of oral treosulfan in patients with platinum-resistant ovarian cancer. METHODS: A phase II trial of oral treosulfan 500 mg per day in 30 females with platinum resistant ovarian cancer. All patients had measurable or evaluable disease. RESULTS: The treatment was well tolerated. One patient (3%) achieved a partial response lasting 12+ months. Seven patients had stable disease for 5.3 months (median) range 4.4-7.5 months. Median time to progression was 11.5 weeks (95% C.L. 11-12 weeks). Median survival was 31 weeks (95% C.L. 30-35 weeks). CONCLUSION:Oral treosulfan in the present schedule is not recommended in platinum resistant ovarian cancer.
Authors: Sven Mahner; Gülten Oskay-Özcelik; Elke Heidrich-Lorsbach; Stefan Fuxius; Harald Sommer; Peter Klare; Antje Belau; Birgit Ruhmland; Thomas Heuser; Heinz Kölbl; Susanne Markmann; Jalid Sehouli Journal: J Cancer Res Clin Oncol Date: 2012-04-15 Impact factor: 4.553
Authors: Jalid Sehouli; Oliver Tomè; Desislava Dimitrova; Oumar Camara; Ingo Bernhard Runnebaum; Hans Werner Tessen; Beate Rautenberg; Radoslav Chekerov; Mustafa Zelal Muallem; Michael Patrick Lux; Tanja Trarbach; Gerald Gitsch Journal: J Cancer Res Clin Oncol Date: 2016-11-28 Impact factor: 4.553